Clostridioides Difficile Infection Treatment Market, by Drug Type (Vancomycin, Metronidazole, Fidaxomicin, and Others (late phase drugs, etc.)), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jan 2023

Code : CMI1492

Pages :182

Formats :

Excel and PDF

Industry : Pharmaceutical

Clostridioides Difficile Infection Treatment Market,Size and Trends

Global Clostridioides Difficile infection treatment market is estimated to be valued at US$ 893.4 million in 2023 and is expected to exhibit a CAGR of 7.13% during the forecast period (2023-2030).

Global Clostridioides Difficile Infection Treatment Market - Driver

Rising prevalence of clostridioides difficile infection

The rising prevalence of clostridioides difficile infection is expected to drive growth of the global clostridiodes difficile infection treatment market over the forecast period. For instance, in August 2022, according to the data published by the National Center for Biotechnology Information, around 453, 000 cases of clostridioides difficile infection were estimated in the year 2021 in the U.S. Furthermore, according to the data published by the Centers for Disease Control and Prevention, it was estimated that in the U.K., the annual incidence of clostridioides difficile infection (Clostridioides Difficile Infection) was 22.2 per 100,000 population in the year 2021.

Increasing research and development activities for prevention of the clostridioides difficile infection

The increasing research and development activities by the key players in the market for launching new treatment therapy or vaccines for preventing clostridioides difficile infection is expected to drive growth of the global clostridiodes difficile infection treatment market. For instance, in March 2022, Pfizer Inc., a pharmaceutical company, announced the results from the Phase 3 CLOVER trial (Clostridium Difficile Vaccine Efficacy Trial). Although the trial did not achieve its pre-specified primary aim of prevention of Clostridioides Difficile Infection, initial assessments of two protocol-defined secondary endpoints revealed a highly favorable impact in lowering Clostridioides Difficile Infection severity and 100% immunisation efficacy in preventing medically attended Clostridioides Difficile Infection. The investigational vaccination was safe and well tolerated, according to safety reviews.